Literature DB >> 22212587

Barriers to hepatitis C treatment.

Christopher E McGowan1, Michael W Fried.   

Abstract

Despite the availability of highly effective therapy for hepatitis C virus (HCV) infection, few patients receive treatment. Barriers arising at multiple levels, from diagnosis to specialist referral, may impede the delivery of hepatitis C care. At the patient level, lack of awareness, fear of side effects, poor adherence and comorbid conditions may prevent treatment. For providers, limited knowledge, lack of availability and communication difficulties may be problematic. At the government and payer level, a lack of promotion, surveillance and funding may interfere. Each of these barriers needs to be addressed if wider implementation of antiviral therapy is to be achieved.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22212587      PMCID: PMC3955982          DOI: 10.1111/j.1478-3231.2011.02706.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  53 in total

1.  Survey of hepatitis B and C in addiction treatment unit.

Authors:  V P Dhopesh; K R Taylor; W M Burke
Journal:  Am J Drug Alcohol Abuse       Date:  2000-11       Impact factor: 3.829

2.  Treatment of chronic hepatitis C in active drug users.

Authors:  G L Davis; J R Rodrigue
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

3.  Treatment of hepatitis C infection in injection drug users.

Authors:  M Backmund; K Meyer; M Von Zielonka; D Eichenlaub
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

4.  Limited success of HCV antiviral therapy in United States veterans.

Authors:  Cathey H Cawthorne; Kelly R Rudat; Mary S Burton; Kyle E Brown; Bruce A Luxon; Christine G Janney; Claus J Fimmel
Journal:  Am J Gastroenterol       Date:  2002-01       Impact factor: 10.864

5.  Surprisingly small effect of antiviral treatment in patients with hepatitis C.

Authors:  Yngve Falck-Ytter; Hemangi Kale; Kevin D Mullen; Steedman A Sarbah; Lucian Sorescu; Arthur J McCullough
Journal:  Ann Intern Med       Date:  2002-02-19       Impact factor: 25.391

6.  Management of hepatitis C patients by primary care physicians in the USA: results of a national survey.

Authors:  T M Shehab; S S Sonnad; A S Lok
Journal:  J Viral Hepat       Date:  2001-09       Impact factor: 3.728

7.  A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.

Authors:  Donna M Evon; Kelly Simpson; Scott Kixmiller; Joseph Galanko; Karen Dougherty; Carol Golin; Michael W Fried
Journal:  Am J Gastroenterol       Date:  2011-07-19       Impact factor: 10.864

8.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

9.  Psychiatric disorders among veterans with hepatitis C infection.

Authors:  Hashem B el-Serag; Mark Kunik; Peter Richardson; Linda Rabeneck
Journal:  Gastroenterology       Date:  2002-08       Impact factor: 22.682

10.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

View more
  51 in total

1.  Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination.

Authors:  A I Soipe; H Razavi; D Razavi-Shearer; O Galárraga; L E Taylor; B D L Marshall
Journal:  Epidemiol Infect       Date:  2016-08-05       Impact factor: 2.451

2.  Hepatitis C virus treatment in the 'real-world': how well do 'real' patients respond?

Authors:  N Deborah Friedman; Joanne H Green; Hanna M Weber; Shiny Stephen; Stephen E Lane; Alvin Y Ting; Jonathan P Watson
Journal:  J Clin Exp Hepatol       Date:  2014-07-25

3.  Health Department Efforts to Increase Hepatitis C RNA Testing Among People Appearing Out of Care: Comparison of Outreach Approaches, New York City, 2017.

Authors:  Rachel Webster; Miranda S Moore; Angelica Bocour; Nirah Johnson; Ann Winters
Journal:  Public Health Rep       Date:  2020-09-04       Impact factor: 2.792

4.  A Simplified Algorithm for the Management of Hepatitis C Infection.

Authors:  Douglas T Dieterich
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-05

5.  Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic.

Authors:  Des Crowley; Walter Cullen; Eamon Laird; John S Lambert; Tina Mc Hugh; Carol Murphy; Marie Claire Van Hout
Journal:  J Transl Int Med       Date:  2017-06-30

Review 6.  Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach.

Authors:  Kenneth E Sherman
Journal:  Clin Infect Dis       Date:  2012-07-26       Impact factor: 9.079

7.  A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care.

Authors:  Christopher E McGowan; Ali Monis; Bruce R Bacon; Josep Mallolas; Fernando L Goncales; Ioannis Goulis; Fred Poordad; Nezam Afdhal; Stefan Zeuzem; Teerha Piratvisuth; Patrick Marcellin; Michael W Fried
Journal:  Hepatology       Date:  2013-04       Impact factor: 17.425

8.  A comparison of modified directly observed therapy to standard care for chronic hepatitis C.

Authors:  Patricia A Cioe; Michael D Stein; Kittichai Promrat; Peter D Friedmann
Journal:  J Community Health       Date:  2013-08

Review 9.  Best strategies for global HCV eradication.

Authors:  Liesl M Hagan; Raymond F Schinazi
Journal:  Liver Int       Date:  2013-02       Impact factor: 5.828

10.  Association of injection drug use with incidence of HIV-associated non-AIDS-related morbidity by age, 1995-2014.

Authors:  Catherine R Lesko; Richard D Moore; Weiqun Tong; Bryan Lau
Journal:  AIDS       Date:  2016-06-01       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.